Menu Search
Equities

Akeso Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4RY:FRA

Akeso Inc

Actions
  • Price (EUR)11.20
  • Today's Change0.50 / 4.67%
  • Shares traded200.00
  • 1 Year change+42.68%
  • Beta0.7380
Data delayed at least 15 minutes, as of Feb 10 2026 13:50 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.

  • Revenue in HKD (TTM)2.83bn
  • Net income in HKD-952.63m
  • Incorporated2019
  • Employees3.53k
  • Location
    Akeso IncNo. 6Shennong Road, Torch Development ZoneZhongshan 528437ChinaCHN
  • Phone+86 76 089873998
  • Fax+86 76 089873900
  • Websitehttps://www.akesobio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.